Literature DB >> 22137664

The urokinase system in the pathogenesis of atherosclerosis.

Bianca Fuhrman1.   

Abstract

Atherogenesis refers to the development of atheromatous plaques in the inner lining of the arteries. These atherosclerotic lesions are characterized by accumulation of monocyte-derived macrophage-foam cells loaded with cholesterol, which eventually undergo apoptotic death, leading finally to formation of the necrotic core of the plaque. Atheroma formation also involves the recruitment of smooth muscle cells (SMC) from the media into the intima, where they proliferate and form the neointima in a process called "remodeling". Cells in the advanced atherosclerotic plaques express high levels of the serine protease urokinase-type plasminogen activator (uPA) and its receptor (uPAR). uPA is a multi-functional multi-domain protein that is not only a regulator of fibrinolysis, but it is also associated with several acute and chronic pathologic conditions. uPA mediate the extracellular matrix (ECM) degradation, and plays a pivotal role in cell adhesion, migration and proliferation, during tissue remodeling. On cell surface uPA binds to the high affinity urokinase receptor, providing a strictly localized proteolysis of ECM proteins. The uPA/uPAR complex also activates intracellular signaling, thus regulating cellular function. An imbalance in the uPA/uPAR system leads to dis-orders in tissue structure and function. This review summarizes recent progress in understanding the role and mechanisms of the uPA/uPAR system in atherogenesis.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22137664     DOI: 10.1016/j.atherosclerosis.2011.10.044

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  36 in total

1.  High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis.

Authors:  Aizhen Yang; Jihong Dai; Zhanli Xie; Robert W Colman; Qingyu Wu; Raymond B Birge; Yi Wu
Journal:  J Immunol       Date:  2014-03-31       Impact factor: 5.422

2.  uPAR signaling is under par for the podocyte course.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2012-12       Impact factor: 4.599

3.  Vitronectin and Urokinase-Type Plasminogen Activator Gene Expression Levels Are Increased in Patients with Coronary Artery In-Stent Restenosis.

Authors:  S M Shafiee; F Noorabad-Ghahroodi; A Amirfarhangi; S R Hosseini-Fard; Z Sharifi; M Najafi
Journal:  Int J Angiol       Date:  2017-04-16

4.  Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor.

Authors:  Jie Hong Hu; Phanith Touch; Jingwan Zhang; Hao Wei; Shihui Liu; Ida K Lund; Gunilla Høyer-Hansen; David A Dichek
Journal:  Cardiovasc Res       Date:  2015-01-23       Impact factor: 10.787

5.  Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.

Authors:  Ayman Samman Tahhan; Salim S Hayek; Pratik Sandesara; Jamal Hajjari; Muhammad Hammadah; Wesley T O'Neal; Heval M Kelli; Ayman Alkhoder; Nima Ghasemzadeh; Yi-An Ko; Hiroshi Aida; Mohamad Mazen Gafeer; Naser Abdelhadi; Kareem Hosny Mohammed; Keyur Patel; Shipra Arya; Jochen Reiser; Viola Vaccarino; Laurence Sperling; Arshed Quyyumi
Journal:  Atherosclerosis       Date:  2017-06-08       Impact factor: 5.162

6.  Urokinase receptor mediates osteogenic differentiation of mesenchymal stem cells and vascular calcification via the complement C5a receptor.

Authors:  Parnian Kalbasi Anaraki; Margret Patecki; Jan Larmann; Sergey Tkachuk; Kerstin Jurk; Hermann Haller; Gregor Theilmeier; Inna Dumler
Journal:  Stem Cells Dev       Date:  2013-12-11       Impact factor: 3.272

7.  Soluble Urokinase Receptor and Chronic Kidney Disease.

Authors:  Salim S Hayek; Sanja Sever; Yi-An Ko; Howard Trachtman; Mosaab Awad; Shikha Wadhwani; Mehmet M Altintas; Changli Wei; Anna L Hotton; Audrey L French; Laurence S Sperling; Stamatios Lerakis; Arshed A Quyyumi; Jochen Reiser
Journal:  N Engl J Med       Date:  2015-11-05       Impact factor: 91.245

Review 8.  Serum suPAR in patients with FSGS: trash or treasure?

Authors:  Rutger J H Maas; Jeroen K J Deegens; Jack F M Wetzels
Journal:  Pediatr Nephrol       Date:  2013-03-21       Impact factor: 3.714

9.  The serum levels of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction.

Authors:  Shu-Jin Wang; Zhong-Sen Qu; Qing-De Zhang; Liang Li; Feng Wang; Bin Zhang; Bang-Li Wu; Yu-Wu Zhao
Journal:  Int J Clin Exp Med       Date:  2015-08-15

10.  Pathway-Specific Aggregate Biomarker Risk Score Is Associated With Burden of Coronary Artery Disease and Predicts Near-Term Risk of Myocardial Infarction and Death.

Authors:  Nima Ghasemzedah; Salim S Hayek; Yi-An Ko; Danny J Eapen; Riyaz S Patel; Pankaj Manocha; Hatem Al Kassem; Mohamed Khayata; Emir Veledar; Dimitrios Kremastinos; Christian W Thorball; Tomasz Pielak; Sergey Sikora; A Maziar Zafari; Stamatios Lerakis; Laurence Sperling; Viola Vaccarino; Stephen E Epstein; Arshed A Quyyumi
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.